What is it about?
To analyse the safety and efficacy of pentoxifylline sustained-release (PTX-SR) treatment in patients with early chronic Peyronie's disease (PD).
Featured Image
Photo by Daria Nepriakhina on Unsplash
Why is it important?
Peyronie’s disease (PD) is a localized connective tissue disorder of the tunica albuginea of the penis and surrounding tissue which results in painful erection, penile curvature and erectile dysfunction (ED). The disorder affects 3.2–8.9% of men in their fifth or sixth decades of age. It has been shown that, of affected men, 80% have ED on testing. Although the exact cause of PD remains unknown, increased levels of TGF β1 in plaques of patients with PD was reported.
Perspectives
At present it seems that a reasonable approach to the nonsurgical treatment of Peyronie's disease might be combined therapy; this should provide synergy between the oral, topical and intralesional drugs. In the present study we have used the criteria of the Oxford Centre for Evidence-Based Medicine. Given the safety profile of pentoxifylline and its favourable effects on various aspects of PD (pain, curvature, and plaque volume), studies with different treatment regimens (perhaps higher doses with a longer duration) are warranted to better elucidate the effects of pentoxifylline on Peyronie's disease.
Dr Mohammad Reza Safarinejad
University of Medical Sceices
Read the Original
This page is a summary of: Retraction statement: A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease, BJU International, February 2015, Wiley,
DOI: 10.1111/bju.13063.
You can read the full text:
Resources
Contributors
The following have contributed to this page
